Zheng Wen, Zhao Juanjuan, Tao Yijing, Guo Mengmeng, Ya Zhou, Chen Chao, Qin Nalin, Zheng Jing, Luo Junmin, Xu Lin
Department of Immunology, Zunyi Medical College, Zunyi, Guizhou 563000, P.R. China.
Department of Medical Physics, Zunyi Medical College, Zunyi, Guizhou 563000, P.R. China.
Oncol Lett. 2018 Sep;16(3):2777-2782. doi: 10.3892/ol.2018.8972. Epub 2018 Jun 15.
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer worldwide. The high mortality rate of NSCLC is due to a limited number of diagnosis being made at an early stage of disease. Therefore, the development of a novel biological marker for the diagnosis and prognosis prediction of NSCLC remains urgent. Current literature shows that microRNA-21 (miRNA-21/miR-21), as an oncogenic miRNA, is involved in the growth, metastasis and apoptosis of NSCLC cells through its control of various target molecules and signaling pathways. Notably, a growing body of evidence further shows that miR-21 is closely associated with the prognosis prediction, recurrence and diagnosis of cancer patients, indicating that miR-21 may be a novel promising biomarker for the diagnosis and prognosis prediction of NSCLC. The present review aimed to provide a summary of recent findings on the associated progression toward finding a novel biomarker for NSCLC.
非小细胞肺癌（NSCLC）是全球最常见的肺癌亚型。NSCLC的高死亡率归因于在疾病早期进行诊断的数量有限。因此，开发一种用于NSCLC诊断和预后预测的新型生物标志物仍然迫在眉睫。当前文献表明，作为一种致癌性微小RNA，微小RNA-21（miRNA-21/miR-21）通过控制各种靶分子和信号通路参与NSCLC细胞的生长、转移和凋亡。值得注意的是，越来越多的证据进一步表明，miR-21与癌症患者的预后预测、复发和诊断密切相关，这表明miR-21可能是一种用于NSCLC诊断和预后预测的新型有前景的生物标志物。本综述旨在总结近期关于寻找NSCLC新型生物标志物相关进展的研究结果。
